My “unicorn” Volvo V90 plug-in hybrid wagon is almost four years old. Here’s how healthy its high-voltage battery is.

Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Bristol Myers Squibb (BMS) has secured another win for Opdivo (nivolumab), becoming the only FDA-approved PD-1 inhibitor for resectable non-small cell lung cancer NSCLC in both a neoadjuvant-only ...

The increasing complexity of embedded systems within battery management necessitates robust testing methodologies that accurately reflect real-world operating ...